Loading
Life sciences · Review
Chembiochem · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Shikonin (SHK) is a red naphthoquinone produced mainly in the roots of Boraginaceae species and has been investigated for anticancer, anti-inflammatory, antimicrobial, neuroprotective, cardioprotective, hepatoprotective, and wound-healing activities. This review critically integrates botanical sources and biosynthesis with pharmacological mechanisms, preclinical evidence, safety, and delivery strategies. Across cancer models, SHK converges on redox imbalance and regulated cell-death programmes, including apoptosis, cell-cycle arrest, autophagy, necroptosis, ferroptosis, and immunogenic cell death, while modulating NF-κB, MAPK, PI3K/Akt, and related signalling networks. However, the evidence is dominated by heterogeneous in vitro experiments and small-animal studies, with limited pharmacokinetic standardisation, incomplete assessment of selectivity toward diseased versus normal tissues, and almost no robust clinical evaluation. Poor aqueous solubility, chemical and photochemical instability, rapid metabolism, route-dependent exposure, and a context-dependent therapeutic window remain central translational barriers. Liposomes, polymeric micelles, nanoparticles, nanogels, nanoemulsions, and ligand- or stimulus-responsive systems can improve dispersion, tissue accumulation, controlled release, and combination therapy; nevertheless, their long-term safety, manufacturing reproducibility, and comparative advantage over free SHK require rigorous validation. SHK should therefore be regarded as a mechanistically versatile therapeutic lead rather than a clinically established treatment. Translation will depend on exposure-response studies, standardised formulations, clinically relevant models, and well-designed human trials.